

# CONFERENCE PROGRAM

**MONDAY MAY 7, 2012**

---

|               |                 |          |
|---------------|-----------------|----------|
| 08:15 – 08:30 | Opening Session | Ballroom |
|---------------|-----------------|----------|

---

OPENING REMARKS AND GREETINGS

**M. Bialer**, Organizing Committee, Israel

GREETINGS

**T. Tomson**, Organizing Committee, Sweden

---

|               |             |          |
|---------------|-------------|----------|
| 08:30 – 10:30 | Symposium I | Ballroom |
|---------------|-------------|----------|

---

## INDICATIONS OVERLAPPING WITH EPILEPSY

Chairs: **E. Abadie**, France  
**R. Katz**, USA

### a) Bipolar Disorder

08:30 CELL-BASED MODELS OF BIPOLAR DISORDER - PAST, PRESENT AND FUTURE  
**A. Harwood**, UK

08:50 Discussion

09:00 CLINICAL POTENTIAL OF AEDs IN BIPOLAR DISORDER  
**R.H. Belmaker**, Israel

09:20 Discussion

## MONDAY MAY 7, 2012 (continued)

### b) Neuropathic Pain

- 09:30 MECHANISMS AND MODELS FOR NEUROPATHIC PAIN  
**M. Devor**, Israel
- 09:50 Discussion
- 10:00 CLINICAL POTENTIAL OF AEDs IN NEUROPATHIC PAIN  
**J. Serra**, Spain
- 10:20 Discussion
- 10:30 *Coffee*

---

11:00 – 12:30 Symposium I (cont.) Ballroom

---

### INDICATIONS OVERLAPPING WITH EPILEPSY

Chairs: **E. Abadie**, France  
**R. Katz**, USA

### c) Migraine

- 11:00 MECHANISMS AND MODELS FOR MIGRAINE  
**M.A. Rogawski**, USA
- 11:20 Discussion
- 11:30 CLINICAL POTENTIAL OF AEDs IN MIGRAINE  
**S.D. Silberstein**, USA
- 11:50 Discussion
- 12:00 INDICATIONS OVERPLAYING WITH EPILEPSY: A  
REGULATORY PERSPECTIVE  
**R. Katz**, USA
- 12:20 Discussion

## TUESDAY, MAY 8, 2012

---

08:00 – 10:00

Session 1 – A

Ballroom

---

### DRUGS IN DEVELOPMENT

Chairs: **M. Bialer**, Israel  
**R.H. Levy**, USA

08:00 BRIVARACETAM  
**S. Lu**, *UCB Inc.*, USA

08:20 Discussion

08:30 2-DEOXY-(D)-GLUCOSE  
Presented by **T.P. Sutula**, University of Wisconsin, USA

08:50 Discussion

09:00 GANAXOLONE  
*Marinus Pharmaceuticals, Inc.*, USA  
Presented by **M.A. Rogawski**, UC Davis, CA, USA

09:20 Discussion

09:30 ICA-105665  
*Pfizer Inc.*, USA  
Presented by **G.C. Rigdon**, Wake Forest, NC, USA

09:50 Discussion

10:00 *Coffee*

**TUESDAY, MAY 8, 2012 (continued)**

---

10:30 – 12:30

Session 1 – B

Ballroom

---

**DRUGS IN DEVELOPMENT**

Chairs: **S.I. Johannessen**, Norway  
**T. Tomson**, Sweden

- 10:30 NAX 5055  
**G. Bulaj**, *NeuroAdjuvants*, USA
- 10:50 Discussion
- 11:00 PERAMPANEL AND OTHER AMPA RECEPTOR  
ANTAGONISTS  
Presented by **M.A. Rogawski**, UC Davis, CA, USA
- 11:20 Discussion
- 11:30 TONABERSAT  
*Upsher-Smith Laboratories, Inc.*, USA  
Presented by **H.S. White**, University of Utah, USA
- 11:50 Discussion
- 12:00 VALPROIC ACID – 2<sup>nd</sup> GENERATION  
Presented by **M. Bialer**, The Hebrew University of Jerusalem,  
Israel
- 12:20 Discussion
- 12:30 *Lunch*

**TUESDAY, MAY 8, 2012 (continued)**

---

13:30 – 15:00

Session 1 – C

Ballroom

---

**DRUGS IN DEVELOPMENT**

Chairs: **T. Tomson**, Sweden  
**H.S. White**, USA

- 13:30 VX-765  
*Vertex Pharmaceuticals Inc*, USA  
Presented by: **J. French**, NYU Comprehensive  
Epilepsy Center, USA
- 13:50 Discussion
- 14:00 YKP3089  
**S.J. Lee** and **M. Kamin**, *SK Life Science*, USA
- 14:20 Discussion
- 14:30 IMEPITOID (AWD 131-138; ELB 138): A NEW  
ANTIPILEPTIC DRUG FOR DOGS WITH EPILEPSY  
*Boehringer-Ingelheim*, Germany  
Presented by **W. Löscher**, University of Veterinary Medicine  
Hannover, Germany
- 14:50 Discussion

**WEDNESDAY, MAY 9, 2012**

---

08:00 – 10:00

Session 2 – A

Ballroom

---

**PROGRESS REPORT ON SECOND-GENERATION TREATMENTS**

Chairs: **J. French**, USA  
**B Schmidt**, Germany

***Drugs (AEDs)***

- 08:00 ESLICARBAZEPINE ACETATE  
*BIAL-Portela & C<sup>a</sup>*, SA, Portugal  
Presented by **E. Trink**a, Paracelsus Medical University, Austria
- 08:20 Discussion
- 08:30 LACOSAMIDE  
**M. De Backer**, *UCB Inc.*, USA
- 08:50 Discussion
- 09:00 LEVETIRACETAM  
**S. Lu**, *UCB Inc.*, USA
- 09:20 Discussion
- 09:30 PREGABALIN  
**H.B. Posner**, *Pfizer Inc.*, USA
- 09:50 Discussion
- 10:00 *Coffee*

**WEDNESDAY, MAY 9, 2012 (continued)**

---

10:30 – 12:30

Session 2 – B

Ballroom

---

**PROGRESS REPORT ON SECOND-GENERATION TREATMENTS**

Chairs: **R.H. Levy**, USA  
**T. Tomson**, Sweden

- 10:30 RETIGABINE  
Presented by **J.A. French**, NYU Comprehensive Epilepsy Center, USA
- 10:50 Discussion
- 11:00 STIRIPENTOL IS ACTIVE IN STATUS EPILEPTICUS MODEL  
*Biocodex*, France  
Presented by **D.D. Mott**, University of South Carolina, USA
- 11:20 Discussion
- 11:30 STIRIPENTOL–CLOBAZAM COMBINATION –  
RETROSPECTIVE ANALYSES  
*Biocodex*, France  
Presented by **C. Chiron**, Hopital Necker-Enfants Malades, Paris, France
- 11:50 Discussion
- 12:00 TOPIRAMATE  
**R. Twyman**, *Johnson & Johnson Pharmaceutical Research & Development*, USA
- 12:20 Discussion
- 12:30 *Lunch*

**WEDNESDAY, MAY 9, 2012 (continued)**

---

13:30 – 15:30

Session 2 – C

Ballroom

---

**PROGRESS REPORT ON SECOND-GENERATION TREATMENTS**

Chairs: **S.I. Johannessen**, Norway  
**E. Trink**a, Austria

***New Formulations***

- 13:30 USL255 - A NEW ONCE DAILY TOPIRAMATE EXTENDED RELEASE (ER) FORMULATION  
*Upsher Smith Laboratories, Inc.*, USA  
Presented by **M. Bialer**, The Hebrew University of Jerusalem, Israel
- 13:50 Discussion
- 14:00 OXCARBAZEPINE MODIFIED-RELEASE (MR) FORMULATION  
*Desitin Arzneimittel GmbH*, Germany  
Presented by **B. Schmidt**, Wittnau, Germany
- 14:20 Discussion
- 14:30 ORFIRIL LONG® COMPARED TO OTHER VALPROIC ACID ER FORMULATIONS IN GENERIC SUBSTITUTION  
*Desitin Arzneimittel GmbH*, Germany  
Presented by **M. Bialer**, The Hebrew University of Jerusalem, Israel
- 14:50 Discussion



**WEDNESDAY, MAY 9, 2012 (continued)**

15:00      INNOVATIVE FORMULATIONS OF  
              BENZODIAZEPINES FOR ACUTE TREATMENT OF  
              SEIZURES  
              Presented by **J. Cloyd**, University of Minnesota, USA

15:20      Discussion

15:30      *Coffee*

## THURSDAY, MAY 10, 2012

---

08:15 – 12:45

Symposium II

Ballroom

---

### **SECURING THE SUCCESSFUL DEVELOPMENT OF AN INVESTIGATIONAL ANTIPILEPTIC DRUG IN THE CURRENT ENVIRONMENT**

Chairs: **R. Katz**, USA  
**R. Twyman**, USA

- 08:15 THE CHANGING LANDSCAPE FOR THERAPEUTIC DEVELOPMENT  
**R. Ranganthan**, Office of Translational Research, NIH, USA
- 08:45 Discussion
- 09:00 NARROW OR BROAD SPECTRUM ANTICONVULSANT ACTIVITY: WHAT DO RESULTS IN ANIMAL SEIZURE AND EPILEPSY MODELS REALLY TELL US ABOUT EFFICACY SPECTRUM IN THE CLINIC?  
**H.S. White**, USA
- 09:20 Discussion
- 09:30 IS KNOWLEDGE OF MECHANISMS OF ACTION AN IMPORTANT CONSIDERATION FOR ADVANCING AN INVESTIGATIONAL NEW DRUG?  
**W. Löscher**, Germany
- 09:50 Discussion
- 10:00 ARE WE ANY CLOSER TO UNDERSTANDING THE PATHOPHYSIOLOGY OF REFRACTORY FOCAL (PARTIAL) ONSET EPILEPSY? HOW WILL THIS KNOWLEDGE CONTRIBUTE TO THE DEVELOPMENT OF MORE EFFECTIVE THERAPIES?  
**H. Potschka**, Germany
- 10:20 Discussion
- 10:30 *Coffee*

## **THURSDAY, MAY 10, 2012 (continued)**

- 11:00      WHAT DOES BIG PHARMA LOOK FOR IN AN  
            INVESTIGATIONAL ANTIEPILEPTIC DRUG?  
            **H. Klitgaard**, Belgium
- 11:20      Discussion
- 11:30      DEMONSTRATING CLINICAL EFFICACY IN THE PATIENT  
            WITH REFRACTORY EPILEPSY: WHY HAS THIS BECOME  
            SO DIFFICULT?  
            **J. French**, USA
- 11:50      Discussion
- 12:00      SYMPOSIUM SUMMARY  
            **R. Twyman**, USA
- 12:20      Discussion
- 12:30      CONCLUDING REMARKS  
            **S.I. Johannessen**, Norway